MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia

Summary

This phase I trial is studying the side effects, best way to give, and best dose of Akt inhibitor MK2206 (MK2206) in treating patients with recurrent or refractory solid tumors or leukemia. MK2206 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2011-01

Primary completion

2013-04

Completion

—

Drugs

Indications